Form 4: Director Karen Drexler Receives Outset Medical Equity Grant

Outset Medical director Karen Drexler was granted 10,667 restricted stock units as part of standard equity compensation.

Summary

• Director Karen Drexler acquired 10,667 shares of common stock in the form of restricted stock units (RSUs).
• The grant was issued on June 4, 2026, at a price of $0.0 per share.
• Following this transaction, Drexler's direct beneficial ownership increased to 21,317 shares.
• Drexler maintains an additional indirect holding of 2,083 shares through the Drexler Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine equity grant for a board member.

Risks

• None identified; this is a standard regulatory disclosure of director compensation.

Future Outlook

The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the medical device industry to ensure board alignment with corporate performance and shareholder interests.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for publicly traded medical technology companies.
• Vesting schedules tied to annual meetings are common benchmarks for board compensation.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 10,667 RSUs on the earlier of June 4, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Outset Medical, OM, Form 4, Insider Trading, Director Compensation, Equity Grant